Addex Therapeutics Key Fundamental And Technical Indicators
| ADXN Stock | USD 6.85 -0.05 -0.72% |
Momentum
OversoldOverbought
49 · Impartial
As of the 7th of May, Addex Therapeutics trades at 6.85 per share. Key technical indicators include risk adjusted performance of -0.01, and Mean Deviation of 3.21. The technical model evaluates historical price movement, trading volume, and volatility patterns to quantify trend strength. Current values are evaluated relative to sector peers and historical ranges.
Addex Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors. Valuation, profitability, and current liquidity needs are evaluated through these accounts.Addex Therapeutics does not currently have any fundamental trend indicators for analysis. Equity Screeners provides expanded screening access beyond individual equity pages. Available filters include financial, valuation, and market-based dimensions.Addex Therapeutics' Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertible bonds.
Shares Outstanding | = | Public Shares | - | Repurchased |
Current Addex Therapeutics Shares Outstanding | 1.23 M |
Core metrics such as Shares Outstanding form the backbone of any value-based review of Addex Therapeutics. A gap between estimated value and market price can hint at mispricing, though other factors matter too. Valuation analysis is typically one part of a broader research process, not a standalone tool.
| Competition |
Addex Therapeutics Fundamental Drivers Relationships
Main Technical Indicators as of May 7, 2026
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.01 | |||
| Market Risk Adjusted Performance | -0.07 | |||
| Mean Deviation | 3.21 | |||
| Coefficient Of Variation | -6,406 | |||
| Standard Deviation | 4.75 | |||
| Variance | 22.56 | |||
| Information Ratio | -0.02 | |||
| Jensen Alpha | -0.09 | |||
| Total Risk Alpha | -0.13 | |||
| Treynor Ratio | -0.08 | |||
| Maximum Drawdown | 22.52 | |||
| Value At Risk | -6.97 | |||
| Potential Upside | 8.28 | |||
| Skewness | 0.0701 | |||
| Kurtosis | 1.7 |
Daily Market Strength Indicators
Market strength indicators for Addex Therapeutics stock provide a framework for assessing security responsiveness. A rising Accumulation/Distribution line alongside rising price confirms institutional buying interest in Addex Therapeutics.
Basic Forecasting Models
Addex Therapeutics' daily price returns decompose into trend, seasonal, and residual components. Divergence between short-term and long-term averages in Addex often signals an upcoming reversal or acceleration.Addex Therapeutics Related Equities
Investors studying Addex Therapeutics often look at related stocks within the Health Care space to gauge pricing and results. Checking cash flow across this peer set helps gauge Addex Therapeutics' relative financial strength.
| Risk & Return | Correlation |
Shares Outstanding Peer Comparison
Peer comparison on Shares Outstanding is one of the most widely used methods for evaluating Addex Therapeutics relative to competitors. Comparing Addex Therapeutics' Shares Outstanding against peers surfaces securities trading below their model-implied intrinsic value estimate in the group.Addex Therapeutics is currently under evaluation in shares outstanding compared to key competitors.
Important Fundamentals
| Return On Equity TTM | -0.73 | |||
| Return On Asset TTM | -0.16 | |||
| Operating Margin TTM | -14.04 | |||
| Current Valuation | 6.56 M | |||
| Shares Outstanding | 1.23 M | |||
| Shares Owned By Institutions | 0.06 % | |||
| Number Of Shares Shorted | 7.26 K | |||
| Price To Book TTM | 1.14 X | |||
| Price To Sales TTM | 53.85 X | |||
| Revenue TTM | 165.22 K | |||
| Gross Profit TTM | -525.65 K | |||
| EBITDA TTM | -2.69 M | |||
| Net Income TTM | 7.06 M | |||
| Cash And Equivalents TTM | 8.81 M | |||
| Cash Per Share TTM | 1.40 X | |||
| Total Debt TTM | 41.99 K | |||
| Debt To Equity TTM | 0.05 % | |||
| Current Ratio TTM | 2.55 X | |||
| Book Value Per Share TTM | 7.78 X | |||
| Cash Flow From Operations TTM | -5.37 M | |||
| Short Ratio TTM | 1.34 X | |||
| Earnings Per Share | -9.03 X | |||
| Target Price | 30.0 | |||
| Trailing Beta | 1.87 | |||
| Market Capitalization TTM | 8.54 M | |||
| Total Asset TTM | 10.68 M | |||
| Retained Earnings TTM | -353.36 M | |||
| Working Capital TTM | 2.74 M | |||
| Current Asset TTM | 32.02 M | |||
| Current Liabilities TTM | 4.82 M | |||
| Net Asset | 10.68 M |
Financial Metrics, Fundamentals & Methodology
Analyzing Addex Therapeutics means reviewing margin quality alongside capital risk exposure. The company is currently operating at a loss. Overall market capitalization tier is micro-cap. In recent filings, Addex Therapeutics reported revenue of 165,221, EPS loss of 9.03, negative operating margin of 14.04% as of the latest reporting period.
Addex Therapeutics metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison. Reported income, balance-sheet, and cash-flow fields adhere to GAAP or IFRS presentation rules.
Editorial review and methodology oversight provided by: Ellen Johnson, Member of Macroaxis Editorial Board